Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer

11 Mar 2019

Abstract excerpt

The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly expanded. There is a need to develop noninvasive biomarkers to guide treatment. We established a highly sensitive method for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma circulating cell-free DNA (cfDNA) and evaluated the AR statuses of patients with CRPC. AR amplification was detectable in VCaP...

Topics

Join the communities discussing this publication.

Cancer Genomics and Diagnostics
PARP inhibition in cancer therapy
Prostate Cancer Treatment and Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30858508
DOI: 10.1038/s41598-019-40719-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancerPMID 30858508Read ↗

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerSemantic proximity Read ↗

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Semantic proximity Read ↗

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.Semantic proximity Read ↗

Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.Semantic proximity Read ↗

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Semantic proximity Read ↗

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.Semantic proximity Read ↗

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancerSemantic proximity Read ↗

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)Semantic proximity Read ↗

Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancerSemantic proximity Read ↗

Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.Semantic proximity Read ↗

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.